Recently, Zacks.com users have been paying close attention to Glaxo (GSK). This makes it worthwhile to examine what the stock has in store.
The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The FDA had earlier declined to approve vadadustat - a Hypoxia-inducible factor–prolyl hydroxylase (HIF-PH) inhibitor - on safety concerns, as it posed an increased risk of blood clot formations and drug-induced injuries to the liver.
Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading actions...